1. Signaling Pathways
  2. GPCR/G Protein
    Neuronal Signaling
  3. Neuropeptide Y Receptor

Neuropeptide Y Receptor

NPY receptor

Neuropeptide Y receptors belong G protein-coupled receptor superfamily and comprise various subtypes. There are currently five cloned NPY receptor subtypes in mammals, termed Y1, Y2, Y4, Y5, and Y6. Neuropeptide Y receptors mediate a variety of physiological responses including feeding and vasoconstriction.

Subtypes Y1, Y2, Y4 and Y5 are expressed in humans. They are present mainly in the central and peripheral nervous systems as well as other tissues, such as the cardiovascular system. Their physiologic ligands are the neurotransmitter Neuropeptide Y and the 2 hormones peptide YY (PYY) and pancreatic polypeptide (PP).

Neuropeptide Y and its receptors regulate important biological and pathophysiological functions, such as blood pressure, neuroendocrine secretions, seizures, neuronal excitability and neuroplasticity.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P3212
    Allo-aca
    Antagonist 99.94%
    Allo-aca, a leptin peptidomimetic, is a potent, specific leptin receptor antagonist peptide. Allo-aca blocks leptin signaling and action in numerous in vitro and in vivo models.
    Allo-aca
  • HY-107725
    BIBO3304
    Antagonist 99.95%
    BIBO3304 is a potent, orally active, and selective neuropeptide Y (NPY) Y1 receptor antagonist, with subnanomolar affinity for both the human and the rat Y1 receptor (IC50=0.38 and 0.72 nM, respectively).
    BIBO3304
  • HY-101986
    BIIE-0246
    Antagonist 99.10%
    BIIE-0246 (AR-H 053591) is a potent and selective NPY2R (neuropeptide Y receptor 2) antagonist with an IC50 value of 15 nM for rat [125I]PYY3-36. BIIE-0246 decreases the expression of p-AKT S473, P-p44/42 MAPK under the NPY-stimulated. BIIE-0246 reduces albuminuria in ADR nephropathy.
    BIIE-0246
  • HY-P0198
    Neuropeptide Y (human,rat,mouse)
    99.94%
    Neuropeptide Y (human,rat,mouse) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.
    Neuropeptide Y (human,rat,mouse)
  • HY-100717
    HT-2157
    Antagonist ≥98.0%
    HT-2157 (SNAP 37889) is a selective, high-affinity, competitive antagonists of galanin-3 receptor (Gal3).
    HT-2157
  • HY-107726
    BIBP3226 TFA
    Antagonist 99.25%
    BIBP3226 TFA is a potent and selective neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor antagonist, with Kis of 1.1, 79, and 108 nM for rNPY Y1, hNPFF2, and rNPFF, respectively. BIBP3226 TFA displays anxiogenic-like effect.
    BIBP3226 TFA
  • HY-P10000
    Peptide YY (PYY) (3-36), Human
    Agonist 98.57%
    Peptide YY (PYY) (3-36), Human is an endogenous appetite suppressing peptide. Peptide YY (PYY) (3-36), Human, a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion.
    Peptide YY (PYY) (3-36), Human
  • HY-P0198A
    Neuropeptide Y (human,rat,mouse) TFA
    99.57%
    Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.
    Neuropeptide Y (human,rat,mouse) TFA
  • HY-P1601
    Neuropeptide Y(29-64)
    99.47%
    Neuropeptide Y(29-64) is a 36 amino acid peptide, a fragment of Neuropeptide Y.
    Neuropeptide Y(29-64)
  • HY-P1514
    Peptide YY (PYY), human
    99.77%
    Peptide YY (PYY) is a gut hormone that regulates appetite and inhibits pancreatic secretion. Peptide YY (PYY) can mediate its effects through the Neuropeptide Y receptors.
    Peptide YY (PYY), human
  • HY-107723
    CGP71683 hydrochloride
    Antagonist 99.44%
    CGP71683 hydrochloride is a competitive neuropeptide Y5 receptor antagonist with a Ki of 1.3 nM, and shows no obvious activity at Y1 receptor (Ki, >4000 nM) and Y2 receptor (Ki, 200 nM) in cell membranes.
    CGP71683 hydrochloride
  • HY-P0208
    [Leu31,Pro34]-Neuropeptide Y (porcine)
    Agonist 98.40%
    [Leu31,Pro34]- Neuropeptide Y (porcine), a Neuropeptide Y (NPY) analog, is a selective NPY Y1 receptor agonist. [Leu31,Pro34]- Neuropeptide Y (porcine) exhibits anxiolytic effects.
    [Leu31,Pro34]-Neuropeptide Y (porcine)
  • HY-P1130
    M871
    Antagonist 99.80%
    M871 (Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide) is a selective galanin receptor type 2 (GalR2) antagonist. M871 exhibits Ki values of 13.1 nM and 420 nM for GalR2 and GalR1, respectively. M871 can be used for research on GalR2-related diseases (such as epilepsy, pain).
    M871
  • HY-P1127
    Galanin (1-30), human
    Agonist 99.91%
    Galanin (1-30), human is a 30-amino acid neuropeptide, and acts as an agonist of GalR1 and GalR2 receptors, with Kis of both 1 nM.
    Galanin (1-30), human
  • HY-P1323A
    [Leu31,Pro34]-Neuropeptide Y(human,rat,mouse) TFA
    Agonist 98.13%
    [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA is a specific neuropeptide Y Y1 receptor agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA slao activates Y4, Y5. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA can increase blood pressure in anesthetized rats and increases food intake.
    [Leu31,Pro34]-Neuropeptide Y(human,rat,mouse) TFA
  • HY-P1723
    Spexin
    Agonist 99.94%
    Spexin (Neuropeptide Q) is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin can function through both central and peripheral actions. Spexin upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy.
    Spexin
  • HY-15411
    MK-0557
    Antagonist 99.80%
    MK-0557 is a highly selective, orally available neuropeptide Y5 receptor antagonist with a Ki of 1.6 nM.
    MK-0557
  • HY-120619
    BMS-193885
    Antagonist 99.08%
    BMS-193885 is a selective neuropeptide Y1 receptor antagonist (Ki=3.3 nM) that competitively blocks the receptor to inhibit NPY-mediated appetite regulation signaling pathways, reduce food intake and inhibit weight gain. BMS-193885 has good blood-brain barrier penetration and is mainly used in the study of obesity and related metabolic diseases.
    BMS-193885
  • HY-107382
    RF9
    Antagonist 98.14%
    RF9 is a potent and selective Neuropeptide FF receptor antagonist, with Ki values of 58 and 75 nM for hNPFF1R and hNPFF2R, respectively.
    RF9
  • HY-P2543
    Neuropeptide Y (3-36) (human, rat)
    Agonist
    Neuropeptide Y (3-36) (human, rat), a neuropeptide Y (NPY) metabolite formed from dipeptidyl peptidase-4 (DPP4), is a selective Y2 receptor agonist. Neuropeptide Y (3-36) (human, rat) is a NPY metabolite formed from dipeptidyl peptidase-4 (DPP4). Neuropeptide Y (3-36) (human, rat) decreases release of norepinephrine via the Y2 receptor.
    Neuropeptide Y (3-36) (human, rat)
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.